Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 13

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Functional characterization of p53 pathway components in the ancient metazoan Trichoplax adhaerens

Siau, Jia Wei, Coffill, Cynthia R., Zhang, Weiyun Villien, Tan, Yaw Sing, Hundt, Juliane, Lane, David, Verma, Chandra, Ghadessy, Farid·2016·Scientific Reports

Abstract

The identification of genes encoding a p53 family member and an Mdm2 ortholog in the ancient placozoan Trichoplax adhaerens advocates for the evolutionary conservation of a pivotal stress-response pathway observed in all higher eukaryotes. Here, we recapitulate several key functionalities ascribed to this known interacting protein pair by analysis of the placozoan proteins (Tap53 and TaMdm2) using both in vitro and cellular assays. In addition to interacting with each other, the Tap53 and TaMdm2 proteins are also able to respectively bind human Mdm2 and p53, providing strong evidence for functional conservation. The key p53-degrading function of Mdm2 is also conserved in TaMdm2. Tap53 retained DNA binding associated with p53 transcription activation function. However, it lacked transactivation function in reporter genes assays using a heterologous cell line, suggesting a cofactor incompatibility. Overall, the data supports functional roles for TaMdm2 and Tap53 and further defines the p53 pathway as an evolutionary conserved fulcrum mediating cellular response to stress.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep33972

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 44

  1. Srivastava, M. et al. The Trichoplax genome and the nature of placozoans. Nature 454, 955–960 (2008). · DOI · Paper page
  2. Putnam, N. H. et al. Sea anemone genome reveals ancestral eumetazoan gene repertoire and genomic organization. Science 317, 86–94 (2007). · DOI · Paper page
  3. Chapman, J. A. et al. The dynamic genome of Hydra. Nature 464, 592–596 (2010). · DOI · Paper page
  4. Lane, D. P. et al. Mdm2 and p53 are highly conserved from placozoans to man. Cell Cycle 9, 540–547 (2010). · DOI
  5. Pankow, S. & Bamberger, C. The p53 tumor suppressor-like protein nvp63 mediates selective germ cell death in the sea anemone Nematostella vectensis. PLoS One 2, e782 (2007). · DOI
  6. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B. & Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51, 6304–6311 (1991).
  7. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V. & Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89, 7491–7495 (1992). · DOI · Paper page
  8. Momand, J., Zambetti, G. P., Olson, D. C., George, D. & Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69, 1237–1245 (1992). · DOI · Paper page
  9. Haupt, Y., Maya, R., Kazaz, A. & Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 387, 296–299 (1997). · DOI · Paper page
  10. Kubbutat, M. H., Jones, S. N. & Vousden, K. H. Regulation of p53 stability by Mdm2. Nature 387, 299–303 (1997). · DOI · Paper page
  11. Honda, R., Tanaka, H. & Yasuda, H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420, 25–27 (1997). · DOI · Paper page
  12. Montes de Oca Luna, R., Wagner, D. S. & Lozano, G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378, 203–206 (1995). · DOI · Paper page
  13. Molchadsky, A., Rivlin, N., Brosh, R., Rotter, V. & Sarig, R. p53 is balancing development, differentiation and de-differentiation to assure cancer prevention. Carcinogenesis 31, 1501–1508 (2010). · DOI
  14. Guidi, L., Eitel, M., Cesarini, E., Schierwater, B. & Balsamo, M. Ultrastructural analyses support different morphological lineages in the phylum Placozoa Grell, 1971. J Morphol 272, 371–378 (2011). · DOI
  15. Schulze, F. E. Trichoplax adhaerens, nov. gen., nov. spec. Zool. Anz. 6, 92–97 (1883).
  16. von der Chevallerie, K., Rolfes, S. & Schierwater, B. Inhibitors of the p53-Mdm2 interaction increase programmed cell death and produce abnormal phenotypes in the placozoon Trichoplax adhaerens (F.E. Schulze). Dev Genes Evol 224, 79–85 (2014). · DOI
  17. Takahashi, T. et al. Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res 52, 2340–2343 (1992).
  18. Kussie, P. et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948–953 (1996). · DOI · Paper page
  19. Brown, C. J. et al. Stapled peptides with improved potency and specificity that activate p53. ACS Chem Biol 8, 506–512 (2013). · DOI · Paper page
  20. Chee, S. M. et al. Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2. PLoS One 9, e104914 (2014). · DOI
  21. Vassilev, L. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844–848 (2004). · DOI · Paper page
  22. Popowicz, G. M. et al. Molecular basis for the inhibition of p53 by Mdmx. Cell Cycle 6, 2386–2392 (2007). · DOI
  23. Wei, S. J. et al. In vitro selection of mutant HDM2 resistant to Nutlin inhibition. PLoS One 8, e62564 (2013). · DOI
  24. Ma, J. et al. A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination. Biochemistry 45, 9238–9245 (2006). · DOI
  25. Yu, G. W. et al. The central region of HDM2 provides a second binding site for p53. Proc Natl Acad Sci USA 103, 1227–1232 (2006). · DOI
  26. Shimizu, H. et al. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo. J Biol Chem 277, 28446–28458 (2002). · DOI
  27. Goh, W., Lane, D. & Ghadessy, F. Development of a novel multiplex in vitro binding assay to profile p53-DNA interactions. Cell Cycle 9, 3030–3038 (2010). · doi:10.4161/cc.9.15.12436
  28. Noureddine, M. A. et al. Probing the functional impact of sequence variation on p53-DNA interactions using a novel microsphere assay for protein-DNA binding with human cell extracts. PLoS Genet 5, e1000462 (2009). · DOI
  29. Dolezelova, P., Cetkovska, K., Vousden, K. H. & Uldrijan, S. Mutational analysis of Mdm2 C-terminal tail suggests an evolutionarily conserved role of its length in Mdm2 activity toward p53 and indicates structural differences between Mdm2 homodimers and Mdm2/MdmX heterodimers. Cell Cycle 11, 953–962 (2012). · DOI
  30. Lohrum, M. A., Ludwig, R. L., Kubbutat, M. H., Hanlon, M. & Vousden, K. H. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 3, 577–587 (2003). · DOI · Paper page
  31. Zhang, Y. et al. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol 23, 8902–8912 (2003). · DOI · Paper page
  32. Zhang, Q., Xiao, H., Chai, S. C., Hoang, Q. Q. & Lu, H. Hydrophilic residues are crucial for ribosomal protein L11 (RPL11) interaction with zinc finger domain of MDM2 and p53 protein activation. J Biol Chem 286, 38264–38274 (2011). · DOI
  33. Lindstrom, M. S., Jin, A., Deisenroth, C., White Wolf, G. & Zhang, Y. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation. Mol Cell Biol 27 (2007). · DOI
  34. Liang, S. H. & Clarke, M. F. A bipartite nuclear localization signal is required for p53 nuclear import regulated by a carboxyl-terminal domain. J Biol Chem 274, 32699–32703 (1999). · DOI · Paper page
  35. Stommel, J. M. et al. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J 18, 1660–1672 (1999). · DOI · Paper page
  36. Kawai, H., Lopez-Pajares, V., Kim, M. M., Wiederschain, D. & Yuan, Z. M. RING domain-mediated interaction is a requirement for MDM2′s E3 ligase activity. Cancer Res 67, 6026–6030 (2007). · DOI
  37. Linke, K. et al. Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ 15, 841–848 (2008). · DOI · Paper page
  38. Pant, V., Xiong, S., Iwakuma, T., Quintas-Cardama, A. & Lozano, G. Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc Natl Acad Sci USA 108, 11995–12000 (2011). · DOI · Paper page
  39. Huang, L. et al. The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo. Proc Natl Acad Sci USA 108, 12001–12006 (2011). · DOI · Paper page
  40. Momand, J., Villegas, A. & Belyi, V. A. The evolution of MDM2 family genes. Gene 486, 23–30 (2011). · DOI · Paper page
  41. Coffill, C. R. et al. The p53-Mdm2 interaction and the E3 ligase activity of Mdm2/Mdm4 are conserved from lampreys to humans. Genes Dev 30, 281–292 (2016). · DOI · Paper page
  42. Muttray, A. F., O’Toole, T. F., Morrill, W., Van Beneden, R. J. & Baldwin, S. A. An invertebrate mdm homolog interacts with p53 and is differentially expressed together with p53 and ras in neoplastic Mytilus trossulus haemocytes. Comp Biochem Physiol B Biochem Mol Biol 156, 298–308 (2010). · DOI
  43. Chen, D. et al. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 121, 1071–1083 (2005). · DOI · Paper page
  44. Dornan, D. et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429 (2004). · DOI · Paper page

Cited by

Metadata

Authors
Siau, J. W., Coffill, C. R., Zhang, W. V., Tan, Y. S., Hundt, J., Lane, D., Verma, C., & Ghadessy, F.
Venue
Scientific Reports
Published
2016-09-28
Volume
6
Issue
1
ISSN
2045-2322
Cited by
13
References
4
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.